Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

The phosphoinositide 3-kinase pathway

Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621 · see citing works

<i>PTEN</i> , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer

Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785 · see citing works

AMPK: a nutrient and energy sensor that maintains energy homeostasis

Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3311 · Cited by 4,602 · see citing works

Cellular survival: a play in three Akts

Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes &amp; Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216 · see citing works

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645 · see citing works

High Frequency of Mutations of the PIK3CA Gene in Human Cancers

Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448 · see citing works

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330 · see citing works

The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104 · see citing works

Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha.

Alessi, D., James, S., Downes, C., Holmes, A. B., Gaffney, P., Reese, C., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 3,047 · see citing works

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · see citing works

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

Yao, J. C., Shah, M. H., Ito, T., Lombard‐Bohas, C., Wolin, E. M., Cutsem, E. V., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,879 · see citing works

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · see citing works

Defining the role of mTOR in cancer

Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833 · see citing works

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,742 · see citing works

Targeting the phosphoinositide 3-kinase pathway in cancer

Liu, P., Cheng, H.-L. M., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,722 · see citing works

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · see citing works

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445 · see citing works

Ras, PI(3)K and mTOR signalling controls tumour cell growth

Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · see citing works

The functions and regulation of the PTEN tumour suppressor

Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926 · see citing works

The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress

Shaw, R. J., Kosmatka, M., Bardeesy, N., Hurley, R. L., Witters, L. A., DePinho, R. A., & Cantley, L. C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308061100 · Cited by 1,797 · see citing works

The emerging mechanisms of isoform-specific PI3K signalling

Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767 · see citing works

Identification of the Tuberous Sclerosis Gene <i>TSC1</i> on Chromosome 9q34

Slegtenhorst, M. V., Hoogt, R. D., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., Ouweland, A. V. D., Halley, D., Young, J., et al. (1997) · Science · doi:10.1126/science.277.5327.805 · Cited by 1,648 · see citing works

Identification and characterization of the tuberous sclerosis gene on chromosome 16

(1993) · Cell · doi:10.1016/0092-8674(93)90618-z · Cited by 1,645 · see citing works

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330 · see citing works

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

Carpten, J. D., Faber, A. L., Horn, C. L., Donoho, G. P., Briggs, S., Robbins, C. M., Hostetter, G. H., Boguslawski, S. J., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,291 · see citing works

PTEN and the PI3-Kinase Pathway in Cancer

Chalhoub, N., & Baker, S. J. (2008) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092311 · Cited by 1,253 · see citing works

Efficacy and safety of sirolimus in lymphangioleiomyomatosis

McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100391 · Cited by 1,099 · see citing works

Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association.

Lee, J.-O., Yang, H.-J., Georgescu, M., Cristofano, A. D., Maehama, T., Shi, Y., Dixon, J., Pandolfi, P., & Pavletich, N. (1999) · Cell · doi:10.1016/s0092-8674(00)81663-3 · Cited by 1,096 · see citing works

Role of Translocation in the Activation and Function of Protein Kinase B

Andjelkovic, M., Alessi, D. R., Meier, R., Fernandez, A., Lamb, N. J. C., Frech, M., Cron, P., Cohen, P., Lucocq, J. M., & Hemmings, B. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31515 · Cited by 1,051 · see citing works

The PTEN–PI3K pathway: of feedbacks and cross-talks

Carracedo, A., & Pandolfi, P. P. (2008) · Oncogene · doi:10.1038/onc.2008.247 · Cited by 883 · see citing works

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas

Bellacosa, A., de Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837 · see citing works

Autophagy as a target for anticancer therapy

Jankú, F., McConkey, D. J., Hong, D. S., & Kurzrock, R. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.71 · Cited by 803 · see citing works

Development of PI3K inhibitors: lessons learned from early clinical trials

Rodon, J. A., Dienstmann, R., Serra, V., & Tabernero, J. M. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.10 · Cited by 770 · see citing works

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.

Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., & Testa, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9267 · Cited by 737 · see citing works

Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis

Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S., Zhang, J., Signoretti, S., Loda, M. F., Roberts, T. M., et al. (2008) · Nature · doi:10.1038/nature07091 · Cited by 691 · see citing works

Genome Sequencing Identifies a Basis for Everolimus Sensitivity

Iyer, G., Hanrahan, A. J., Milowsky, M. I., Al‐Ahmadie, H. A., Scott, S. N., Janakiraman, M., Pirun, M., Sander, C., Socci, N. D., Ostrovnaya, I., et al. (2012) · Science · doi:10.1126/science.1226344 · Cited by 688 · see citing works

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Bendell, J. C., Rodon, J. A., Burris, H. A., de Jonge, M. J. A., Verweij, J., Birle, D. C., Demanse, D., Buck, S. S. D., Ru, Q. C., Peters, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 687 · see citing works

Class I PI3K in oncogenic cellular transformation

Zhao, L., & Vogt, P. K. (2008) · Oncogene · doi:10.1038/onc.2008.244 · Cited by 598 · see citing works

Deregulated Akt3 Activity Promotes Development of Malignant Melanoma

Stahl, J. M., Sharma, A. K., Cheung, M., Zimmerman, M., Cheng, J. Q., Bosenberg, M., KESTER, M. A., Sandirasegarane, L., & Robertson, G. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1399 · Cited by 595 · see citing works

Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers

Lui, V. W. Y., Hedberg, M. L., Li, H., Vangara, B. S., Pendleton, K. P., Zeng, Y., Lu, Y., Zhang, Q., Du, Y., Gilbert, B. R., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0103 · Cited by 594 · see citing works

LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin

Shackelford, D. B., Abt, E., Gerken, L., Vasquez, D. S., Seki, A., Leblanc, M., Wei, L., Fishbein, M. C., Czernin, J., Mischel, P. S., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.008 · Cited by 585 · see citing works

The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations

Huang, C., Mandelker, D. L., Schmidt‐Kittler, O., Samuels, Y., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., Gabelli, S. B., & Amzel, L. M. (2007) · Science · doi:10.1126/science.1150799 · Cited by 564 · see citing works

The Gβγ Sensitivity of a PI3K Is Dependent upon a Tightly Associated Adaptor, p101

Stephens, L., Eguinoa, A., Erdjument‐Bromage, H., Lui, M. L., Cooke, F. T., Coadwell, J., Smrcka, A., Thelen, M., Cadwallader, K. A., Tempst, P., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80187-7 · Cited by 557 · see citing works

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

Yap, T. A., Li, Y., Patnaik, A., Fearen, I., Olmos, D., Papadopoulos, K. P., Baird, R. D., Delgado, L., Taylor, A. B., Lupinacci, L. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5263 · Cited by 540 · see citing works

AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer

Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., McNear, C. J., Kim, J. J., Hennessy, B. T., Tseng, H., Pochanard, P., Kim, S. Y., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.012 · Cited by 524 · see citing works

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation

Furet, P., Guagnano, V., Fairhurst, R. A., Imbach, P. A., Bruce, I., Knapp, M. S., Fritsch, C. M., Blasco, F., Blanz, J., Aichholz, R., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.007 · Cited by 492 · see citing works

Rheb fills a GAP between TSC and TOR

Manning, B. (2003) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.09.003 · Cited by 483 · see citing works

High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability

Cheung, L. W. T., Hennessy, B. T., Li, J., Yu, S., Myers, A. P., Djordjevic, B., Lu, Y., Stemke‐Hale, K., Dyer, M. D., Zhang, F., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0039 · Cited by 469 · see citing works

HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells

Knuefermann, C., Lü, Y., Liu, B., Jin, W., Liang, K., Wu, L., Schmidt, M., Mills, G. B., Mendelsohn, J. M., & Fan, Z. (2003) · Oncogene · doi:10.1038/sj.onc.1206394 · Cited by 452 · see citing works

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations

Jankú, F., Wheler, J. J., Westin, S. N., Moulder, S., Naing, A., Tsimberidou, A. M., Fu, S., Falchook, G. S., Hong, D. S., Garrido‐Laguna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1196 · Cited by 448 · see citing works

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

Burris, H. A. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2043-3 · Cited by 446 · see citing works

mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling

Rodrik-Outmezguine, V. S., Chandarlapaty, S., Pagano, N. C., Poulikakos, P. I., Scaltriti, M., Moskatel, E., Baselga, J., Guichard, S., & Rosen, N. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0085 · Cited by 442 · see citing works

Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

Zhao, L., & Vogt, P. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712169105 · Cited by 438 · see citing works

Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors

Wagner, A. J., Malinowska-Kołodziej, I., Morgan, J. A., Qin, W., Fletcher, C. D. �., Vena, N., Ligon, A. H., Antonescu, C. R., Ramaiya, N. H., Demetri, G. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.2981 · Cited by 399 · see citing works

Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function

Jaber, N. L., Dou, Z., Chen, J., Catanzaro, J. M., Jiang, Y.-P., Ballou, L. M., Selinger, E. S., Ouyang, X., Lin, R. Z., Zhang, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112848109 · Cited by 386 · see citing works

Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs

Markman, B., Dienstmann, R., & Tabernero, J. M. (2010) · Oncotarget · doi:10.18632/oncotarget.188 · Cited by 353 · see citing works

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

Nicolantonio, F. D., Arena, S., Tabernero, J. M., Grosso, S., Molinari, F., Macarulla, T. M., Russo, M., Cancelliere, C., Zecchin, D., Mazzucchelli, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci37539 · Cited by 343 · see citing works

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

Jankú, F., Tsimberidou, A. M., Garrido‐Laguna, I., Wang, X., Luthra, R., Hong, D. S., Naing, A., Falchook, G. S., Moroney, J. W., Piha-Paul, S. A., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0994 · Cited by 331 · see citing works

Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas

Ruggeri, B., Huang, L., Wood, M., Cheng, J. Q., & Testa, J. R. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199802)21:2 · Cited by 329 · see citing works

A Secreted PTEN Phosphatase That Enters Cells to Alter Signaling and Survival

Hopkins, B. D., Fine, B. M., Steinbach, N., Dendy, M., Rapp, Z., Shaw, J. M., Pappas, K., Yu, J. S., Hodakoski, C., Mense, S. M., et al. (2013) · Science · doi:10.1126/science.1234907 · Cited by 325 · see citing works

Evidence That Lymphangiomyomatosis Is Caused by TSC2 Mutations: Chromosome 16p13 Loss of Heterozygosity in Angiomyolipomas and Lymph Nodes from Women with Lymphangiomyomatosis

Smolarek, T. A., Wessner, L. L., McCormack, F. X., Mylet, J. C., Menon, A. G., & Henske, E. P. (1998) · The American Journal of Human Genetics · doi:10.1086/301804 · Cited by 312 · see citing works

The Tumor Suppressor PTEN Is Exported in Exosomes and Has Phosphatase Activity in Recipient Cells

Putz, U., Howitt, J. A., Doan, A., Goh, C., Low, L., Silke, J., & Tan, S. (2012) · Science Signaling · doi:10.1126/scisignal.2003084 · Cited by 312 · see citing works

Frequent Inactivation of PTEN by Promoter Hypermethylation in Microsatellite Instability-High Sporadic Colorectal Cancers

Goel, A., Arnold, C. N., Niedzwiecki, D., Carethers, J. M., Dowell, J. M., Wasserman, L., Compton, C., Mayer, R. J., Bertagnolli, M. M., & Boland, C. R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-2401-2 · Cited by 302 · see citing works

PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials

Jankú, F., Wheler, J. J., Naing, A., Falchook, G. S., Hong, D. S., Stepanek, V. M. T., Fu, S., Piha-Paul, S. A., Lee, J. J., Luthra, R., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1726 · Cited by 300 · see citing works

Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models

Lin, J. M., Sampath, D., Nannini, M., Lee, B. B., Degtyarev, M. Y., Oeh, J., Savage, H. M., Guan, Z., Hong, R., Kassees, R., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3072 · Cited by 295 · see citing works

Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance

Ihle, N. T., Lemos, R., Wipf, P., Yacoub, A., Mitchell, C., Siwak, D. R., Mills, G. B., Dent, P., Kirkpatrick, D. L., & Powis, G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6656 · Cited by 275 · see citing works

A novel AKT3 mutation in melanoma tumours and cell lines

Davies, M. A., Stemke‐Hale, K., Tellez, C. S., Calderone, T. L., Deng, W., Prieto, V. G., Lazar, A. J., Gershenwald, J. E., & Mills, G. B. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604637 · Cited by 273 · see citing works

Integrative Genomic and Proteomic Analyses Identify Targets for Lkb1-Deficient Metastatic Lung Tumors

Carretero, J., Shimamura, T., Rikova, K., Jackson, A. L., Wilkerson, M. D., Borgman, C. L., Buttarazzi, M., Sanofsky, B. A., McNamara, K. L., Brandstetter, K. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.026 · Cited by 243 · see citing works

Discovery of 4-Amino- N -[(1 S )-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7 H -pyrrolo[2,3- d ]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases

Addie, M., Ballard, P. G., Buttar, D., Crafter, C., Currie, G. S., Davies, B. R., Debreczeni, J. E., Dry, H., Dudley, P., Greenwood, R. D. R., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301762v · Cited by 236 · see citing works

Regulation of phosphoinositide 3-kinase expression in health and disease

Kok, K. B., Geering, B., & Vanhaesebroeck, B. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.01.003 · Cited by 231 · see citing works

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

Wallin, J. J., Edgar, K. A., Guan, J., Berry, M., Prior, W. W., Lee, L. B., Lesnick, J., Lewis, C. T., Nonomiya, J., Pang, J., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0446 · Cited by 231 · see citing works

Akt inhibitors in clinical development for the treatment of cancer

Pal, S. K., Reckamp, K. L., Yu, H., & Figlin, R. A. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.520701 · Cited by 227 · see citing works

Promoter methylation of the PTEN gene is a common molecular change in breast cancer

García, J. M., Silva, J., Peña, C., García‐Barberán, V., Rodríguez, R., Cruz, M. Á., Cantos, B., Provencio, M., España, P., & Bonilla, F. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20062 · Cited by 224 · see citing works

<i>PIK3CA</i> and <i>PTEN</i> Mutations in Uterine Endometrioid Carcinoma and Complex Atypical Hyperplasia

Hayes, M. P., Wang, H., Espinal-Witter, R., Douglas, W., Solomon, G. J., Baker, S. J., & Ellenson, L. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1375 · Cited by 218 · see citing works

Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer

Sato, T., Nakashima, A., Guo, L., Coffman, K., & Tamanoi, F. (2010) · Oncogene · doi:10.1038/onc.2010.28 · Cited by 214 · see citing works

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014

Pike, K. G., Malagu, K., Hummersone, M., Menear, K. A., Duggan, H. M. E., Gomez, S., Martin, N. M. B., Ruston, L., Pass, S. L., & Pass, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.01.019 · Cited by 210 · see citing works

Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

Bhagwat, S. V., Gokhale, P. C., Crew, A. P. A., Cooke, A., Yao, Y., Mantis, C., Kahler, J., Workman, J. E., Bittner, M., Dudkin, L., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1099 · Cited by 197 · see citing works

PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs

Weigelt, B., Warne, P. H., & Downward, J. (2011) · Oncogene · doi:10.1038/onc.2011.42 · Cited by 190 · see citing works

New Insights into mTOR Signaling: mTORC2 and Beyond

Alessi, D. R., Pearce, L. R., & García‐Martínez, J. M. (2009) · Science Signaling · doi:10.1126/scisignal.267pe27 · Cited by 188 · see citing works

Diverse Mechanisms of AKT Pathway Activation in Human Malignancy

Cheung, M., & Testa, J. R. (2013) · Current Cancer Drug Targets · doi:10.2174/1568009611313030002 · Cited by 184 · see citing works

A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

Hong, D. S., Bowles, D. W., Falchook, G. S., Messersmith, W. A., George, G. C., O’Bryant, C. L., Vo, A. C. H., Klucher, K. M., Herbst, R. S., Eckhardt, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0714 · Cited by 169 · see citing works

Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer Agent

Ni, J., Liu, Q., Xie, S., Carlson, C. B., Von, T., Vogel, K. W., Riddle, S., Benes, C. H., Eck, M. J., Roberts, T. M., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0003 · Cited by 162 · see citing works

Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide

Prasad, G., Sottero, T. L., Yang, X., Mueller, S., James, C. D., Weiss, W. A., Polley, M. Y., Ozawa, T., Berger, M. S., Aftab, D. T., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq193 · Cited by 157 · see citing works

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia

Wiestner, A. U. (2012) · Blood · doi:10.1182/blood-2012-05-423194 · Cited by 151 · see citing works

ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer

Stern, D. F. (2008) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-008-9083-7 · Cited by 150 · see citing works

mTOR kinase inhibitors as potential cancer therapeutic drugs

Sun, S. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.06.017 · Cited by 147 · see citing works

THE AMERICAN SOCIETY OF HEMATOLOGY

Alexander, W. (2009) · Blood · doi:10.1182/blood.v114.22.r23.r23 · Cited by 146 · see citing works

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

Mahadevan, D., Chiorean, E. G., Harris, W. B., Hoff, D. D. V., Stejskal-Barnett, A., Qi, W., Anthony, S. P., Younger, A., Rensvold, D., Cordova-Marks, F. M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.06.027 · Cited by 136 · see citing works

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma

Naing, A., Aghajanian, C. A., Raymond, É., Olmos, D., Schwartz, G., Oelmann, E. M., Grinsted, L. M., Burke, W., Taylor, R., Kaye, S. B., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.368 · Cited by 131 · see citing works

LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition

Mahoney, C., Choudhury, B., Davies, H. R., Edkins, S., Greenman, C., van Haaften, G. W., Mironenko, T., Santarius, T., Stevens, C., Stratton, M. R., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604886 · Cited by 128 · see citing works

Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment

Zeng, Z., Shi, Y. X., Tsao, T., Qiu, Y., Kornblau, S. M., Baggerly, K., Liu, W., Jessen, K., Liu, Y., Kantarjian, H. M., et al. (2012) · Blood · doi:10.1182/blood-2011-11-393934 · Cited by 125 · see citing works

Lkb1inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy

Contreras, C. M., Akbay, E. A., Gallardo, T. D., Haynie, J. M., Sharma, S. V., Tagao, O., Bardeesy, N. M., Takahashi, M., Settleman, J., Wong, K., et al. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.004440 · Cited by 125 · see citing works

Isolation of DNA Sequences Amplified at Chromosome 19q13.1–q13.2 Including theAKT2Locus in Human Pancreatic Cancer

Miwa, W., Yasuda, J., Murakami, Y., Yashima, K., Sugano, K., Sekine, T., Kono, A., Egawa, S., Yamaguchi, K. D., Hayashizaki, Y., et al. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1280 · Cited by 123 · see citing works

INPP4B: the New Kid on the PI3K Block

Agoulnik, I., Hodgson, M., Bowden, W. A., & Ittmann, M. (2011) · OncoTarget · doi:10.18632/oncotarget.260 · Cited by 110 · see citing works

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

Janes, M. R., Vu, C., Mallya, S., Shieh, M., Limon, J. J., Li, L., Jessen, K., Martin, M., Ren, P., Lilly, M. B., et al. (2012) · Leukemia · doi:10.1038/leu.2012.276 · Cited by 109 · see citing works

PTEN at a glance

Shi, Y., Paluch, B. E., Wang, X., & Jiang, X. (2012) · Journal of Cell Science · doi:10.1242/jcs.093765 · Cited by 106 · see citing works

Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH

橋本, 毅., Mori, N., Tamesa, T., Okada, T., Kawauchi, S., Oga, A., Furuya, T., Tangoku, A., Oka, M., & Sasaki, K. (2004) · Modern Pathology · doi:10.1038/modpathol.3800107 · Cited by 101 · see citing works

Mutations in the humanLKB1/STK11gene

Launonen, V. (2005) · Human Mutation · doi:10.1002/humu.20222 · Cited by 98 · see citing works

1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas

Ichimura, K., Vogazianou, A. P., Liu, L., Pearson, D. M., Bäcklund, L. M., Plant, K., Baird, K., Langford, C. F., Gregory, S. G., & Collins, V. P. (2007) · Oncogene · doi:10.1038/sj.onc.1210848 · Cited by 97 · see citing works

PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes

Jankú, F., Wheler, J. J., Naing, A., Stepanek, V. M. T., Falchook, G. S., Fu, S., Garrido‐Laguna, I., Tsimberidou, A. M., Piha-Paul, S. A., Moulder, S., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.716 · Cited by 97 · see citing works

The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/ Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance

Hoang, B. Q., Benavides, A., Shi, Y., Yang, Y., Frost, P., Gera, J., & Lichtenstein, A. K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.304626 · Cited by 76 · see citing works

Emerging Treatments in the Management of Tuberous Sclerosis Complex

Kohrman, M. H. (2012) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2012.02.015 · Cited by 66 · see citing works

Selective Inhibition of Phosphoinositide 3-Kinase p110α Preserves Lymphocyte Function*

So, L., Yea, S. S., Oak, J. S., Lu, M., Manmadhan, A., Ke, Q. H., Janes, M. R., Kessler, L. V., Kucharski, J. M., Li, L., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.379446 · Cited by 66 · see citing works

Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study

Juric, D., Rodon, J. A., Gonzalez-Angulo, A. M., Burris, H. A., Bendell, J. C., Berlin, J. D., Middleton, M. R., Bootle, D., Boehm, M., Schmitt, A., et al. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-ct-01 · Cited by 62 · see citing works

New molecularly targeted therapies for glioblastoma multiforme.

Polívka, J., Polívka, J., Rohan, V., Topolčan, O., & Ferda, J. (2012) · PubMed · Cited by 59 · see citing works

Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms

Pymar, L. S., Platt, F. M., Askham, J. M., Morrison, E. E., & Knowles, M. A. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn098 · Cited by 58 · see citing works

Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex

Yalon, M., Ben‐Sira, L., Constantini, S., & Toren, A. (2010) · Child s Nervous System · doi:10.1007/s00381-010-1222-y · Cited by 50 · see citing works

2011 ASCO Annual Meeting

上野, 秀., & 上野, 誠. (2011) · Medical Entomology and Zoology · Cited by 47 · see citing works

GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic Leukemia

Macias‐Perez, I., & Flinn, I. W. (2012) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0142-1 · Cited by 47 · see citing works

Lovastatin Induces Multiple Stress Pathways Including LKB1/AMPK Activation That Regulate Its Cytotoxic Effects in Squamous Cell Carcinoma Cells

Ma, L., Niknejad, N., Gorn‐Hondermann, I., Dayekh, K., & Dimitroulakos, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046055 · Cited by 47 · see citing works

Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells

Blaser, B., Waselle, L., Dormond-Meuwly, A., Dufour, M., Roulin, D., Demartines, N., & Dormond, O. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-86 · Cited by 47 · see citing works

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.

Wiestner, A. U. (2012) · PubMed · doi:10.1182/asheducation-2012.1.88 · Cited by 45 · see citing works

Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma

Kang, S., Seo, S., Chang, H. J., Yoo, C. W., Park, S. Y., & Dong, S. (2008) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01172.x · Cited by 43 · see citing works

Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs

Ogita, S., & LoRusso, P. M. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0176-7 · Cited by 40 · see citing works

BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study

Juric, D., Rodon, J. A., Gonzalez-Angulo, A., Burris, H. A., Bendell, J. C., Berlin, J., Middleton, M. R., Bootle, D., Boehm, M., Schmitt, A., et al. (2012) · Cancer Research · Cited by 39 · see citing works

Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex

Cappellano, A. M., Senerchia, A. A., Adolfo, F., Paiva, P. M., Pinho, R. S., Covic, A. N., Cavalheiro, S., & Saba, N. (2013) · Child s Nervous System · doi:10.1007/s00381-013-2170-0 · Cited by 33 · see citing works

Abstract P6-10-07: Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA mutant ER-positive (ER+) metastatic breast cancer (MBC)

Juric, D., Argilés, G., Burris, H., Gonzalez-Angulo, A., Saura, C., Quadt, C., Douglas, M., Demanse, D., Buck, S., & Baselga, J. M. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-p6-10-07 · Cited by 31 · see citing works

A rationale for mTOR inhibitors as chemoprevention agents in Peutz-Jeghers syndrome

Kuwada, S. K., & Burt, R. W. (2011) · Familial Cancer · doi:10.1007/s10689-011-9471-9 · Cited by 27 · see citing works

Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program

Reynolds, C. P., Kang, M. H., Carol, H., Lock, R. B., Gorlick, R. G., Kolb, E. A., Kurmasheva, R. T., Keir, S. T., Maris, J. M., Billups, C. A., et al. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24301 · Cited by 20 · see citing works

Response of Lymphangioleiomyomatosis to a Mammalian Target of Rapamycin Inhibitor (Temsirolimus) –Based Treatment

Piha-Paul, S. A., Hong, D. S., & Kurzrock, R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5928 · Cited by 14 · see citing works

Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.

Cheng, H., Merika, E., Syrigos, K., & Saif, M. W. (2011) · PubMed · Cited by 14 · see citing works

PTEN assessment and PI3K/mTOR inhibitors: Importance of simultaneous assessment of MAPK pathway aberrations.

Jankú, F., Broaddus, R. R., Bakkar, R. M., Hong, D. S., Stepanek, V. M. T., Naing, A., Falchook, G. S., Fu, S., Wheler, J. J., Piha-Paul, S. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.10510 · Cited by 12 · see citing works

Pills of PTEN? In and out for tumor suppression

Papa, A., Chen, M., & Pandolfi, P. P. (2013) · Cell Research · doi:10.1038/cr.2013.103 · Cited by 11 · see citing works

Studies of NVP-BEZ235 in Melanoma

Sznol, J. A., Jilaveanu, L. B., & Kluger, H. M. (2013) · Current Cancer Drug Targets · doi:10.2174/1568009611313020006 · Cited by 10 · see citing works

Cowden syndrome (multiple hamartoma syndrome)

Aslam, A. M., & Coulson, I. H. (2013) · Clinical and Experimental Dermatology · doi:10.1111/ced.12140 · Cited by 9 · see citing works

PD09-05: SU2C Phase Ib Study of pan-PI3K Inhibitor BKM120 Plus Aromatase Inhibitor Letrozole in ER+/HER2− Metastatic Breast Cancer (MBC).

Mayer, I. A., Balko, J. M., Kuba, M., Sanders, M., Yap, J. T., Li, Y., Winer, E. P., & Arteaga, C. (2011) · Cancer Research · doi:10.1158/0008-5472.sabcs11-pd09-05 · Cited by 7 · see citing works

Bringing target-matched PI3King from the bench to the clinic

Jankú, F. (2013) · Cell Cycle · doi:10.4161/cc.25118 · Cited by 6 · see citing works

A phase I study of BKM120, a novel oral selective phosphatidylinositol-3-kinase (PI3K) inhibitor, in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer.

Nagaraj, G., Ma, C. X., Luo, J. R., & Ellis, M. J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.tps664 · Cited by 5 · see citing works

246 Aberrations in PIK3CA, PTEN, and MAPK (KRAS, NRAS, BRAF) in 1,656 Patients and Experience with Early-phase Protocols with PI3K/AKT/mTOR Inhibitors

Jankú, F., Hong, D. S., Fu, S., Piha-Paul, S. A., Naing, A., Falchook, G. S., Tsimberidou, A. M., Stepanek, V. M. T., Wheler, J. J., & Kurzrock, R. (2012) · European Journal of Cancer · doi:10.1016/s0959-8049(12)72044-0 · Cited by 4 · see citing works

Targeting the PI3K pathway in cancer: are we making headway?

Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033 · see citing works

A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer

Braicu, C., Buse, M., Busuioc, C. I., Drulă, R., Gulei, D., Ráduly, L., Alexandru Vasile, R. U. S. U., Irimie, A., Atanasov, A. G., Slaby, O., et al. (2019) · Cancers · doi:10.3390/cancers11101618 · Cited by 940 · see citing works

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

Yu, L., Wei, J., & Liu, P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 785 · see citing works

Health benefits of polyphenols: A concise review

Rana, A., Samtiya, M., Dhewa, T., Mishra, V., & Aluko, R. E. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14264 · Cited by 800 · see citing works

Tumor biomarkers for diagnosis, prognosis and targeted therapy

Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 772 · see citing works

Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy

Tewari, D., Patni, P., Bishayee, A., Sah, A. N., & Bishayee, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.008 · Cited by 655 · see citing works

PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives

Asati, V., Mahapatra, D. K., & Bharti, S. K. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.01.012 · Cited by 618 · see citing works

Anticancer Drug Discovery Based on Natural Products: From Computational Approaches to Clinical Studies

Patil, P. C., Kaleem, M., Mishra, R., Ray, S., Ahmad, A., Verma, D., Bhayye, S. S., Dubey, R., Singh, H. N., & Kumar, S. (2024) · Biomedicines · doi:10.3390/biomedicines12010201 · Cited by 429 · see citing works

Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers

Liu, Y., Cheng, Y., Xu, Y., Wang, Z., Du, X., Li, C., Peng, J., Gao, L., Liang, X., & Ma, C. (2017) · Oncogene · doi:10.1038/onc.2017.209 · Cited by 367 · see citing works

mTOR in Brain Physiology and Pathologies

Bockaert, J., & Marin, P. (2015) · Physiological Reviews · doi:10.1152/physrev.00038.2014 · Cited by 360 · see citing works

The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances

Saraei, P., Asadi, I., Kakar, M. A., & Moradikor, N. (2019) · Cancer Management and Research · doi:10.2147/cmar.s200059 · Cited by 354 · see citing works

Targeting cellular pathways in glioblastoma multiforme

Pearson, J. R. D., & Regad, T. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.40 · Cited by 343 · see citing works

Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance

Rozengurt, E., Soares, H. P., & Sinnet-Smith, J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0330 · Cited by 316 · see citing works

Formononetin: A Review of Its Anticancer Potentials and Mechanisms

Tay, K. C., Tan, L. T., Chan, C. K., Hong, S. L., Chan, K., Yap, W. H., Pusparajah, P., Lee, L., & Goh, B. H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00820 · Cited by 299 · see citing works

Strategies to Inhibit Myc and Their Clinical Applicability

Whitfield, J. R., Beaulieu, M.-È., & Soucek, L. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00010 · Cited by 295 · see citing works

Metabolic reprogramming in cancer: Mechanisms and therapeutics

Nong, S., Han, X., Yu, X., Qian, Y., Wei, Y., Zhang, T., Tian, K., Shen, K., Yang, J., & Ma, X. (2023) · MedComm · doi:10.1002/mco2.218 · Cited by 292 · see citing works

Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence

Xu, Y., Li, N., Xiang, R., & Sun, P. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.04.004 · Cited by 282 · see citing works

Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies

Pouyan, A., Ghorbanlo, M., Eslami, M., Jahanshahi, M., Ziaei, E., Salami, A., Mokhtari, K., Shahpasand, K., Farahani, N., Meybodi, T. E., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02267-0 · Cited by 299 · see citing works

Targeting the Warburg effect: A revisited perspective from molecular mechanisms to traditional and innovative therapeutic strategies in cancer

Liao, M., Yao, D., Wu, L., Luo, C., Wang, Z., Zhang, J., & Liu, B. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.12.003 · Cited by 280 · see citing works

Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients

Jankú, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.005 · Cited by 245 · see citing works

Glutamine Metabolism in Cancer

Li, T., & Le, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77736-8_2 · Cited by 240 · see citing works

Helicobacter pylori virulence factor CagA promotes tumorigenesis of gastric cancer via multiple signaling pathways

Yong, X., Tang, B., Li, B., Xie, R., Hu, C.-J., Luo, G., Qin, Y., Dong, H. F., & Yang, S. (2015) · Cell Communication and Signaling · doi:10.1186/s12964-015-0111-0 · Cited by 236 · see citing works

Molecular targets of curcumin for cancer therapy: an updated review

Kasi, P. D., Rajavel, T., Skalicka‐Woźniak, K., Nabavi, S. F., Daglia, M., Bishayee, A., Pazoki–Toroudi, H., & Nabavi, S. M. (2016) · Tumor Biology · doi:10.1007/s13277-016-5183-y · Cited by 216 · see citing works

Vascular and Metabolic Implications of Novel Targeted Cancer Therapies

Li, W., Croce, K., Steensma, D. P., McDermott, D. F., Ben‐Yehuda, O., & Moslehi, J. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.025 · Cited by 202 · see citing works

Radiation-induced signaling pathways that promote cancer cell survival (Review)

HEIN, A. L., OUELLETTE, M. M., & YAN, Y. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2614 · Cited by 201 · see citing works

HPV: Molecular pathways and targets

Gupta, S., Kumar, P. N., & Das, B. C. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.03.003 · Cited by 194 · see citing works

Mechanistic Understanding of Curcumin’s Therapeutic Effects in Lung Cancer

Tajuddin, W. N. B. W. M., Lajis, N. H., Abas, F., Othman, I., & Naidu, R. (2019) · Nutrients · doi:10.3390/nu11122989 · Cited by 161 · see citing works

Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice

Zhang, S., Song, X., Cao, D., Xu, Z., Fan, B., Che, L., Hu, J., Chen, B., Dong, M., Pilo, M. G., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.006 · Cited by 152 · see citing works

Targeting PI3K/AKT/mTOR Signaling Pathway in Pancreatic Cancer: From Molecular to Clinical Aspects

Stanciu, S., Radu, F. I., Ștefani, C., Miricescu, D., Stănescu-Spînu, I.-I., Greabu, M., Totan, A., & Jinga, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710132 · Cited by 144 · see citing works

Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme

Polívka, J., Polívka, J., Holubec, L., Kubíková, T., Přibáň, V., Hes, O., Pivovarčíková, K., & Třešková, I. (2017) · Anticancer Research · doi:10.21873/anticanres.11285 · Cited by 138 · see citing works

CXCL5/CXCR2 axis promotes bladder cancer cell migration and invasion by activating PI3K/AKT-induced upregulation of MMP2/MMP9

Gao, Y., Guan, Z., Chen, J., Xie, H., YANG, Z., Fan, J., Wang, X., & Li, L. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3041 · Cited by 136 · see citing works

The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines

Riquelme, I., Tapia, Ó., Espinoza, J. A., Leal, P., Buchegger, K., Sandoval, A., Bizama, C., Araya, J. C., Peek, R. M., & Roa, J. C. (2016) · Pathology & Oncology Research · doi:10.1007/s12253-016-0066-5 · Cited by 135 · see citing works

PI3K/AKT/mTOR pathway-related long non-coding RNAs: roles and mechanisms in hepatocellular carcinoma

Wu, Y., Zhang, Y., Qin, X., Geng, H., Zuo, D., & Zhao, Q. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105195 · Cited by 132 · see citing works

A prodrug of green tea polyphenol (–)-epigallocatechin-3-gallate (Pro-EGCG) serves as a novel angiogenesis inhibitor in endometrial cancer

Wang, J., Man, G. C. W., Chan, T. H., Kwong, J., & Wang, C. C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.09.054 · Cited by 127 · see citing works

Bioactive Polyphenols and Neuromodulation: Molecular Mechanisms in Neurodegeneration

Meo, F. D., Valentino, A., Petillo, O., Peluso, G., Filosa, S., & Crispi, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072564 · Cited by 127 · see citing works

Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer

Mortazavi, M., Moosavi, F., Martini, M., Giovannetti, E., & Firuzi, O. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103749 · Cited by 126 · see citing works

Underlying Mechanisms for Distant Metastasis - Molecular Biology

Pachmayr, E., Treese, C., & Stein, U. (2017) · Visceral Medicine · doi:10.1159/000454696 · Cited by 123 · see citing works

The PI3K/AKT pathway promotes fracture healing through its crosstalk with Wnt/β-catenin

Dong, J., Xu, X., Zhang, Q., Yuan, Z., & Tan, B. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112137 · Cited by 123 · see citing works

Glutamine Metabolism in Cancer

Li, T., Copeland, C., & Le, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-65768-0_2 · Cited by 130 · see citing works

Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer

Quan, Z., Yang, Y., Zheng, H., Zhan, Y., Luo, J., Ning, Y., & Fan, S. (2022) · Journal of Cancer · doi:10.7150/jca.77619 · Cited by 124 · see citing works

Human Papillomaviruses as Infectious Agents in Gynecological Cancers. Oncogenic Properties of Viral Proteins

Haręża, D. A., Wilczyński, J. R., & Paradowska, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031818 · Cited by 127 · see citing works

Recent advances in the clinical development of immune checkpoint blockade therapy

Ghahremanloo, A., Soltani, A., Modaresi, S. M. S., & Hashemy, S. I. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00456-w · Cited by 119 · see citing works

Transcript and protein expression decoupling reveals RNA binding proteins and miRNAs as potential modulators of human aging

Wei, Y.-N., Hu, H.-Y., Xie, G.-C., Fu, N., Ning, Z.-B., Zeng, R., & Khaitovich, P. (2015) · Genome Biology · doi:10.1186/s13059-015-0608-2 · Cited by 117 · see citing works

A multi-targeted approach to suppress tumor-promoting inflammation

Samadi, A. K., Bilsland, A. E., Georgakilas, A. G., Amedei, A., Amin, A., Bishayee, A., Azmi, A. S., Lokeshwar, B. L., Grue, B., Panis, C., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.006 · Cited by 113 · see citing works

Soy Isoflavones and Breast Cancer Cell Lines: Molecular Mechanisms and Future Perspectives

Uifălean, A., Schneider, S., Ionescu, C. M. L., Lalk, M., & Iuga, C. A. (2015) · Molecules · doi:10.3390/molecules21010013 · Cited by 111 · see citing works

Asiatic acid attenuates CCl 4 -induced liver fibrosis in rats by regulating the PI3K/AKT/mTOR and Bcl-2/Bax signaling pathways

Wei, L., Chen, Q., Guo, A., Fan, J., Wang, R., & Zhang, H. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.04.016 · Cited by 108 · see citing works

Signaling pathways in HPV‐associated cancers and therapeutic implications

Chen, J. (2015) · Reviews in Medical Virology · doi:10.1002/rmv.1823 · Cited by 107 · see citing works

Emerging agents that target signaling pathways to eradicate colorectal cancer stem cells

Silva, V. R., Santos, L. D. S., Dias, R. B., Quadros, C. A., & Bezerra, D. P. (2021) · 癌症：英文版 · doi:10.1002/cac2.12235 · Cited by 106 · see citing works

Curcumin: a therapeutic strategy in cancers by inhibiting the canonical WNT/β-catenin pathway

Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1320-y · Cited by 104 · see citing works

Role of Forkhead Box Class O proteins in cancer progression and metastasis

Kim, C.-G., Lee, H., Gupta, N., Ramachandran, S., Kaushik, I., Srivastava, S., Kim, S., & Srivastava, S. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.07.007 · Cited by 103 · see citing works

Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma

Rahmani, F., Ziaeemehr, A., Shahidsales, S., Gharib, M., Khazaei, M., Ferns, G. A., Ryzhikov, M., Avan, A., & Hassanian, S. M. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29333 · Cited by 103 · see citing works

MYC and therapy resistance in cancer: risks and opportunities

Donati, G., & Amati, B. B. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13319 · Cited by 99 · see citing works

Network pharmacology based research into the effect and mechanism of Yinchenhao Decoction against Cholangiocarcinoma

Chen, Z., Lin, T., Liao, X., Li, Z., Lin, R., Qi, X., Chen, G., Sun, L., & Lin, L. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00423-4 · Cited by 99 · see citing works

PI3K-mTORC2 but not PI3K-mTORC1 regulates transcription of HIF2A/EPAS1 and vascularization in neuroblastoma

Mohlin, S., Hamidian, A., von Stedingk, K., Bridges, E., Wigerup, C., Bexell, D., & Påhlman, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0708 · Cited by 104 · see citing works

Celastrol and Its Role in Controlling Chronic Diseases

Venkatesha, S. H., & Moudgil, K. D. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-41334-1_12 · Cited by 97 · see citing works

Comprehensive anti-tumor effect of Brusatol through inhibition of cell viability and promotion of apoptosis caused by autophagy via the PI3K/Akt/mTOR pathway in hepatocellular carcinoma

Ye, R., Dai, N., He, Q., Guo, P., Xiang, Y., Zhang, Q., Hong, Z., & Zhang, Q. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.065 · Cited by 98 · see citing works

Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma

Xu, S., Liu, D., Chang, T., Wen, X., Ma, S., Sun, G., Wang, L., Chen, S., Xu, Y., & Zhang, H. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.938259 · Cited by 98 · see citing works

At the Crossroads Between Neurodegeneration and Cancer: A Review of Overlapping Biology and Its Implications

Houck, A. L., Seddighi, S., & Driver, J. A. (2018) · Current Aging Science · doi:10.2174/1874609811666180223154436 · Cited by 95 · see citing works

Resveratrol suppresses colon cancer growth by targeting the AKT/STAT3 signaling pathway

Li, D., Wang, G., Jin, G., Yao, K., Zhao, Z., Bie, L., Guo, Y., Li, N., Deng, W., Chen, X., et al. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3969 · Cited by 95 · see citing works

Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer

Barra, F., Evangelisti, G., Desideri, L. F., Domenico, S. D., Ferraioli, D., Vellone, V. G., Cian, F. D., & Ferrero, S. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1558202 · Cited by 95 · see citing works

m6A RNA modification modulates PI3K/Akt/mTOR signal pathway in Gastrointestinal Cancer

Zhao, Q., Zhao, Y., Hu, W., Zhang, Y., Wu, X., Lu, J., Li, M., Li, W., Wu, W., Wang, J., et al. (2020) · Theranostics · doi:10.7150/thno.42971 · Cited by 95 · see citing works

PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis

Bădoiu, S. C., Greabu, M., Miricescu, D., Stănescu-Spînu, I.-I., Ilinca, R., Bălan, D. G., Balcangiu‐Stroescu, A.-E., Mihai, D. A., Văcăroiu, I. A., Ștefani, C., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098391 · Cited by 99 · see citing works

Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer

Weisner, J., Landel, I., Reintjes, C., Uhlenbrock, N., Trajkovic‐Arsic, M., Dienstbier, N., Hardick, J., Ladigan, S., Lindemann, M., Smith, S. P., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2861 · Cited by 94 · see citing works

Autophagy in acute leukemias: A double-edged sword with important therapeutic implications

Evangelisti, C., Evangelisti, C., Chiarini, F., Lonetti, A., Buontempo, F., Neri, L. M., McCubrey, J. A., & Martelli, A. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.09.023 · Cited by 94 · see citing works

Beyond controlling cell size: functional analyses of S6K in tumorigenesis

Wu, X., Xie, W., Xie, W.-X., Wei, W.-Y., & Guo, J.-P. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05081-4 · Cited by 77 · see citing works

Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies

Mossenta, M., Busato, D., Bo, M. D., & Toffoli, G. (2020) · Cancers · doi:10.3390/cancers12061668 · Cited by 90 · see citing works

MYCN-enhanced Oxidative and Glycolytic Metabolism Reveals Vulnerabilities for Targeting Neuroblastoma

Oliynyk, G., Ruiz-Pérez, M. V., Sainero‐Alcolado, L., Dzieran, J., Zirath, H., Gallart‐Ayala, H., Wheelock, C. E., Johansson, H. J., Nilsson, R., Lehtiö, J., et al. (2019) · iScience · doi:10.1016/j.isci.2019.10.020 · Cited by 87 · see citing works

Sex and Gender Differences in Kidney Cancer: Clinical and Experimental Evidence

Peired, A. J., Campi, R., Angelotti, M. L., Antonelli, G., Conte, C., Lazzeri, E., Becherucci, F., Calistri, L., Serni, S., & Romagnani, P. (2021) · Cancers · doi:10.3390/cancers13184588 · Cited by 89 · see citing works

Rho, ROCK and actomyosin contractility in metastasis as drug targets

Rodríguez‐Hernández, I., Cantelli, G., Fanshawe, B., & Sanz‐Moreno, V. (2016) · F1000Research · doi:10.12688/f1000research.7909.1 · Cited by 88 · see citing works

Autophagy Modulators: Mechanistic Aspects and Drug Delivery Systems

Tavakol, S., Ashrafizadeh, M., Deng, S., Azarian, M., Abdoli, A., Motavaf, M., Poormoghadam, D., Khanbabaei, H., Afshar, E. G., Mandegary, A., et al. (2019) · Biomolecules · doi:10.3390/biom9100530 · Cited by 89 · see citing works

HIV‐1, HAART and cancer: A complex relationship

Shmakova, A., Germini, D., & Vassetzky, Y. S. (2019) · International Journal of Cancer · doi:10.1002/ijc.32730 · Cited by 86 · see citing works

Lycorine Promotes Autophagy and Apoptosis via TCRP1/Akt/mTOR Axis Inactivation in Human Hepatocellular Carcinoma

Yu, H., Qiu, Y., Pang, X., Li, J., Wu, S., Yin, S., Han, L., Zhang, Y., Jin, C., Gao, X., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0498 · Cited by 86 · see citing works

Reactive Oxygen Species-Mediated c-Jun NH 2 -Terminal Kinase Activation Contributes to Hepatitis B Virus X Protein-Induced Autophagy via Regulation of the Beclin-1/Bcl-2 Interaction

Zhong, L., Shu, W., Dai, W., Gao, B., & Xiong, S. (2017) · Journal of Virology · doi:10.1128/jvi.00001-17 · Cited by 83 · see citing works

Identification of new immune target and signaling for cancer immunotherapy

Narote, S., Desai, S. A., Patel, V. P., Deshmukh, R., Raut, N., & Dapse, S. (2025) · Cancer Genetics · doi:10.1016/j.cancergen.2025.03.004 · Cited by 92 · see citing works

The potentials of carbon monoxide-releasing molecules in cancer treatment: An outlook from ROS biology and medicine

Vo, T. T. T., Vo, Q. C., Tuan, V. P., Wee, Y., Cheng, J. H.-C., & Lee, I. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102124 · Cited by 81 · see citing works

The Heterogeneity of Lipid Metabolism in Cancer

Park, J. K., Coffey, N. J., Limoges, A., & Le, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77736-8_3 · Cited by 79 · see citing works

Cyclooxygenase-2 in tumor-associated macrophages promotes metastatic potential of breast cancer cells through Akt pathway

Gan, L., Qiu, Z., Huang, J., Li, Y., Huang, H., Xiang, T., Wan, J., Hui, T., Lin, Y. S., Li, H., et al. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.15943 · Cited by 79 · see citing works

LncRNA‐XIST/microRNA‐126 sponge mediates cell proliferation and glucose metabolism through the IRS1/PI3K/Akt pathway in glioma

Cheng, Z., Luo, C., & Guo, Z. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29440 · Cited by 78 · see citing works

Drug discovery targeting the mTOR pathway

Martelli, A. M., Buontempo, F., & McCubrey, J. A. (2018) · Clinical Science · doi:10.1042/cs20171158 · Cited by 76 · see citing works

Bergamottin Suppresses Metastasis of Lung Cancer Cells through Abrogation of Diverse Oncogenic Signaling Cascades and Epithelial-to-Mesenchymal Transition

Ko, J., Nam, D., Um, J., Jung, S. Y., Sethi, G., & Ahn, K. S. (2018) · Molecules · doi:10.3390/molecules23071601 · Cited by 76 · see citing works

Multiplexed Fluorescence Imaging of ERK and Akt Activities and Cell-cycle Progression

Maryu, G., Matsuda, M., & Aoki, K. (2016) · Cell Structure and Function · doi:10.1247/csf.16007 · Cited by 76 · see citing works

miR-182 and miR-135b Mediate the Tumorigenesis and Invasiveness of Colorectal Cancer Cells via Targeting ST6GALNAC2 and PI3K/AKT Pathway

Li, J., Luo, S., Ren, X. S., Li, Y., Hu, J., Liu, B., Zhao, L., Shan, Y., & Zhou, H. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4755-z · Cited by 74 · see citing works

Therapeutic targeting of replicative immortality

Yaswen, P., MacKenzie, K. L., Keith, W. N., Hentosh, P., Rodier, F., Zhu, J., Firestone, G. L., Matheu, A., Carnero, A., Bilsland, A. E., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.007 · Cited by 74 · see citing works

Anticancer natural medicines: An overview of cell signaling and other targets of anticancer phytochemicals

Akhtar, M. F., Saleem, A., Rasul, A., Baig, M. M. F. A., Bin-Jumah, M. N., & Abdel‐Daim, M. M. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173488 · Cited by 73 · see citing works

PI3K: A Crucial Piece in the RAS Signaling PuzzlePreprint

Krygowska, A. A., & Castellano, E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031450 · Cited by 71 · see citing works

Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician

Lheureux, S., Denoyelle, C., Ohashi, P. S., Bono, J. S. D., & Mottaghy, F. M. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3695-3 · Cited by 71 · see citing works

Interferons: Reprogramming the Metabolic Network against Viral Infection

Raniga, K., & Liang, C. (2018) · Viruses · doi:10.3390/v10010036 · Cited by 69 · see citing works

The epigallocatechin gallate derivative Y6 inhibits human hepatocellular carcinoma by inhibiting angiogenesis in MAPK/ERK1/2 and PI3K/AKT/ HIF-1α/VEGF dependent pathways

Liao, Z.-H., Zhu, H., Chen, Y., Chen, R.-L., Fu, L.-X., Li, L., Zhou, H., Zhou, J., & Liang, G. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112852 · Cited by 71 · see citing works

Casticin-Induced Inhibition of Cell Growth and Survival Are Mediated through the Dual Modulation of Akt/mTOR Signaling Cascade

Lee, J. H., Kim, C., Um, J., Sethi, G., & Ahn, K. S. (2019) · Cancers · doi:10.3390/cancers11020254 · Cited by 69 · see citing works

Chlorogenic acid inhibits proliferation and induces apoptosis in A498 human kidney cancer cells via inactivating PI3K/Akt/mTOR signalling pathway

Wang, X., Liu, J., Xie, Z., Rao, J., Xu, G., Huang, K., Li, W., & Yin, Z. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13095 · Cited by 69 · see citing works

Cell Signaling Pathways That Promote Radioresistance of Cancer Cells

Ouellette, M. M., Zhou, S., & Yan, Y. (2022) · Diagnostics · doi:10.3390/diagnostics12030656 · Cited by 69 · see citing works

Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer

Kuwano, M., Sonoda, K., Murakami, Y., Watari, K., & Ono, M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.002 · Cited by 65 · see citing works

Overexpression of PIK3R1 promotes hepatocellular carcinoma progression

Ai, X., Xiang, L., Huang, Z., Zhou, S., Zhang, S., Zhang, T., & Jiang, T. (2018) · Biological Research · doi:10.1186/s40659-018-0202-7 · Cited by 65 · see citing works

Current Perspective on the Natural Compounds and Drug Delivery Techniques in Glioblastoma Multiforme

Behl, T., Sharma, A., Sharma, L. K., Sehgal, A., Singh, S., Sharma, N., Zengin, G., BUNGAU, S. G., Toma, M. M., Gîtea, D., et al. (2021) · Cancers · doi:10.3390/cancers13112765 · Cited by 66 · see citing works

Cancer stem cell in prostate cancer progression, metastasis and therapy resistance

Verma, P., Shukla, N., Kumari, S., Ansari, M. S., Gautam, N. K., & Patel, G. K. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188887 · Cited by 65 · see citing works

Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver

Li, X., Tao, J., Cigliano, A., Sini, M., Caldéraro, J., Azoulay, D., Wang, C., Liu, Y., Jiang, L., Evert, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3546 · Cited by 65 · see citing works

BCAT1 Activates PI3K/AKT/mTOR Pathway and Contributes to the Angiogenesis and Tumorigenicity of Gastric Cancer

Shu, X., Zhan, P., Sun, L., Yu, L., Liu, J., Sun, L., Yang, Z., Ran, Y., & Sun, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.659260 · Cited by 64 · see citing works

Association of PI3K/AKT/mTOR Pathway with Cancer and Its Therapeutic Implications

Saleem, S., Bashir, I., Khan, M. S., & Ahanger, M. S. (2025) · Springer eBooks · doi:10.1007/978-981-96-2763-9_3 · Cited by 3 · see citing works

Targeting the PI3K pathway in cancer: are we making headway?

Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033 · see citing works

Targeting the PI3K-AKT-mTOR signaling network in cancer

Khan, K. H., Yap, T. A., Li, Y., & Cunningham, D. (2013) · 癌症：英文版 · doi:10.5732/cjc.013.10057 · Cited by 214 · see citing works

PI3K/AKT/mTOR Signalling Pathways as Therapeutic Targets: From Biomarkers to Clinical Outcomes.

Greshnikov, V. (2026) · Journal of chemical health risks · doi:10.52783/jchr.v16.i2.13542

PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside

Alzahrani, A. S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.009 · Cited by 1,063 · see citing works